Drug Trial Radar · NCT05739981
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Feb 10, 2023
Primary completion
Jun 30, 2027
Study completion Aug 30, 2028
Sponsor
- Lead sponsor
- ImunonIndustry
- Sponsor type
- Industry
- Collaborators
- Breakthrough Cancer Research
- First posted
- Feb 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.
Conditions
- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
Interventions
PaclitaxelDrug
Paclitaxel 175 mg/m2 IV
CarboplatinDrug
Carboplatin AUC 5-6 IV
BevacizumabDrug
BEV 15 mg/kg IV administration will be included with each cycle EXCEPT the following cycles: \[1\] Cycle 1, \[2\] the last cycle of neoadjuvant therapy immediately preceding ICS, and \[3\] the first cycle of adjuvant chemotherapy (i.e., first cycle after ICS). During the maintenance phase, BEV 15 mg/kg will be administered every 3 weeks as a single agent until disease progression or unacceptable toxicity for a maximum of an additional 18 cycles. In total, BEV may be administered up to 24 cycles. FDA approved BEV biosimilars may be used in this study in place of BEV.
IMNN-001Drug
IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Minimal Residual DiseaseTime frame: 8 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Johns Hopkins Medicine SKCCC
Baltimore, Maryland · Completed
Memorial Sloan Kettering Cancer Center
New York, New York · Active not recruiting
OU Health, Stephenson Cancer Center
Oklahoma City, Oklahoma · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.